Shares of Harrow Health (NASDAQ:HROW) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price target of $11.38 for the company and are expecting that the company will post ($0.02) earnings per share for the current quarter, according to Zacks. Zacks has also given Harrow Health an industry rank of 95 out of 256 based on the ratings given to related companies.
HROW has been the subject of a number of research reports. TheStreet raised shares of Harrow Health from a “d-” rating to a “c” rating in a report on Wednesday, May 1st. ValuEngine lowered shares of Harrow Health from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Lake Street Capital set a $15.00 target price on shares of Harrow Health and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Zacks Investment Research raised shares of Harrow Health from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Tuesday.
In other news, Director Robert J. Kammer sold 6,500 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $6.89, for a total transaction of $44,785.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert J. Kammer sold 10,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $5.78, for a total transaction of $57,800.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,000 shares of company stock worth $154,000. Corporate insiders own 12.43% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Harrow Health by 0.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,118,280 shares of the company’s stock worth $9,729,000 after acquiring an additional 9,112 shares during the period. BlackRock Inc. boosted its position in Harrow Health by 273.3% during the 2nd quarter. BlackRock Inc. now owns 430,524 shares of the company’s stock worth $3,745,000 after acquiring an additional 315,209 shares during the period. Cadence Capital Management LLC acquired a new position in Harrow Health during the 2nd quarter worth $2,483,000. Renaissance Technologies LLC boosted its position in Harrow Health by 18.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,146,506 shares of the company’s stock worth $9,975,000 after acquiring an additional 178,700 shares during the period. Finally, Acadian Asset Management LLC boosted its position in Harrow Health by 40.8% during the 2nd quarter. Acadian Asset Management LLC now owns 560,597 shares of the company’s stock worth $4,878,000 after acquiring an additional 162,459 shares during the period. 36.28% of the stock is currently owned by institutional investors.
Shares of Harrow Health stock traded up $0.07 during trading hours on Wednesday, reaching $5.22. 2,061 shares of the company’s stock were exchanged, compared to its average volume of 336,228. Harrow Health has a 1 year low of $2.22 and a 1 year high of $8.99. The company has a market capitalization of $133.88 million, a P/E ratio of 8.57 and a beta of 0.06. The business has a fifty day moving average of $7.29 and a two-hundred day moving average of $6.16. The company has a quick ratio of 3.60, a current ratio of 3.87 and a debt-to-equity ratio of 0.56.
Harrow Health (NASDAQ:HROW) last released its earnings results on Wednesday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). Harrow Health had a return on equity of 50.32% and a net margin of 51.32%. The business had revenue of $13.52 million for the quarter, compared to analysts’ expectations of $12.55 million. As a group, research analysts predict that Harrow Health will post -0.09 EPS for the current year.
About Harrow Health
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Read More: Green Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.